Biomerica Story

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:4em;'>BI</div>
BMRA -- USA Stock  

USD 6.20  0.78  11.17%

Biomerica Enterprise Value is projected to increase significantly based on the last few years of reporting. The past year's Enterprise Value was at 83.23 Million. The current year Invested Capital is expected to grow to about 10.6 M, whereas Average Assets are forecasted to decline to about 9.5 M. As many baby boomers are still indifferent towards healthcare space, it makes sense to go over Biomerica. We will cover the possibilities of making Biomerica into a steady grower in February. In this post, I will also go over a few different drivers affecting Biomerica's products and services, and explain how it may impact Biomerica investors.
Published over a week ago
View all stories for Biomerica | View All Stories
Here is why Biomerica (NASDAQ:BMRA) can still attract investors
We provide trade advice to complement the prevailing expert consensus on Biomerica. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.

How important is Biomerica's Liquidity

Biomerica financial leverage refers to using borrowed capital as a funding source to finance Biomerica ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Biomerica financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Biomerica's total debt and its cash.

How Biomerica utilizes its cash?

To perform a cash flow analysis of Biomerica, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Biomerica is receiving and how much cash it distributes out in a given period. The Biomerica cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Biomerica Net Cash Flow from Operations is projected to decrease significantly based on the last few years of reporting. The past year's Net Cash Flow from Operations was at (3.87 Million)

What did Biomerica file with SEC?

The SEC filings are financial statements or other formal documents of Biomerica that are regularly submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make SEC filings and fintech professionals rely on these filings for information about companies they are evaluating for investment purposes. Please note, most SEC filings are available online through the SEC's EDGAR database. Please check here for more information.
Please note, although all public domestic companies are required to submit their filings via EDGAR, not all public companies are available through our service. Also, keep in mind that the actual annual reports to Biomerica shareholders may or may not be submitted as SEC does not always require it.
Financial Statements and Exhibits. Other Events. Regulation FD Disclosure
View
Submission of Matters to a Vote of Security Holders. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
Unclassified Corporate Event
View
Please note, although all public domestic companies are required to submit their filings via EDGAR, not all public companies are available through our service. Also, keep in mind that the actual annual reports to Biomerica shareholders may or may not be submitted as SEC does not always require it.

Acquisition by Sloan Steven of 25000 shares of Biomerica subject to Rule 16b-3

Legal trades by Biomerica insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Biomerica insider trading alert for grant of non-qualified stock option by Sloan Steven, Chief Financial Officer, on 11th of December 2020. This event was filed by Biomerica Inc with SEC on 2020-12-11. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

What is driving Biomerica Investor Appetite?

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Biomerica has an asset utilization ratio of 118.36 percent. This suggests that the company is making $1.18 for each dollar of assets. An increasing asset utilization means that Biomerica is more efficient with each dollar of assets it utilizes for everyday operations.

Is Biomerica getting out of control?

Current potential upside is at 6.42. Biomerica exhibits very low volatility with skewness of 1.34 and kurtosis of 10.42. However, we advise investors to further study Biomerica technical indicators to make sure all market info is available and is reliable.

Our Final Take On Biomerica

Whereas other entities in the diagnostics & research industry are either recovering or due for a correction, Biomerica may not be as strong as the others in terms of longer-term growth potentials. With an impartial outlook on the current market volatility, it may be better to hold off any inventment activity and neither buy nor short any shares of Biomerica at this time. The Biomerica risk-reward trade off is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Biomerica.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Biomerica. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com